AR072906A1 - Nucleosidos modificados utiles como antivirales - Google Patents
Nucleosidos modificados utiles como antiviralesInfo
- Publication number
- AR072906A1 AR072906A1 ARP090102985A ARP090102985A AR072906A1 AR 072906 A1 AR072906 A1 AR 072906A1 AR P090102985 A ARP090102985 A AR P090102985A AR P090102985 A ARP090102985 A AR P090102985A AR 072906 A1 AR072906 A1 AR 072906A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- amino
- heterocycloalkyl
- heteroaryl
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000000304 alkynyl group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 4
- -1 amino acid ester Chemical class 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical group 0.000 abstract 3
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000003282 alkyl amino group Chemical group 0.000 abstract 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 2
- 125000005129 aryl carbonyl group Chemical group 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 208000001490 Dengue Diseases 0.000 abstract 1
- 206010012310 Dengue fever Diseases 0.000 abstract 1
- 208000005176 Hepatitis C Diseases 0.000 abstract 1
- 208000003152 Yellow Fever Diseases 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000001769 aryl amino group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 208000025729 dengue disease Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000004001 thioalkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Composiciones farmacéuticas y uso para preparar medicamentos utiles para dengue, fiebre amarilla, hepatitis C, etc. Reivindicacion 1: Un compuesto de la formula (1), o una sal farmacéuticamente aceptable del mismo en donde: X es CH o CR6; R1 es halogeno, NR7R8 u OR9; R2 es H, halogeno, o NR7R8; R3 es H, alquilo, alquenilo, alquinilo, arilo, cicloalquilo, hetero-cicloalquilo o heteroarilo, cada uno de los cuales está opcionalmente sustituido con uno o más sustituyentes; R4 es H, acilo o un éster de aminoácido; R5 es H, acilo o un éster de aminoácido; R6 es alquilo, alquenilo, alquinilo, arilo, cicloalquilo, hetero-cicloalquilo, heteroarilo, halogeno, ciano, nitro, hidroxilo, alcoxilo, tioalquilo, amino, alquil-amino, carboxilo, carboxamida o alquiloxi-carbonilo, cada uno de los cuales está opcionalmente sustituido con uno o más sustituyentes; R7 y R8 se seleccionan independientemente a partir del grupo que consiste en H, alquilo, alquenilo, alquinilo, arilo, cicloalquilo, hetero-cicloalquilo, heteroarilo, amino, alquil-amino, aril-amino, hidroxilo, alcoxilo, aril-carbonilo y alquil-carbonilo, cada uno de los cuales está opcionalmente sustituido con uno o mas sustituyentes; y R9 es H, alquilo, alquenilo, alquinilo, arilo, cicloalquilo, hetero-cicloalquilo, heteroarilo, alquil-carbonilo o aril-carbonilo, cada uno de !os cuales está opcionalmente sustituido con uno o más sustituyentes; en donde R4 y R5 no son ambos H.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08161933 | 2008-08-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR072906A1 true AR072906A1 (es) | 2010-09-29 |
Family
ID=39736919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090102985A AR072906A1 (es) | 2008-08-06 | 2009-08-04 | Nucleosidos modificados utiles como antivirales |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20100144655A1 (es) |
| AR (1) | AR072906A1 (es) |
| WO (1) | WO2010015643A1 (es) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012082436A2 (en) * | 2010-12-03 | 2012-06-21 | Epizyme, Inc. | Modulators of histone methyltransferase, and methods of use thereof |
| AU2011336272A1 (en) * | 2010-12-03 | 2013-06-20 | Epizyme, Inc. | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof |
| DK2646444T3 (da) | 2010-12-03 | 2016-06-27 | Epizyme Inc | Substituerede purin- og 7-deazapurinforbindelser som modulatorer af epigenetiske enzymer |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| US20130012470A1 (en) * | 2011-07-07 | 2013-01-10 | Humanitas Technology, LLC | Antiviral compositions and methods of their use |
| LT3495367T (lt) | 2012-06-13 | 2021-02-25 | Incyte Holdings Corporation | Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| EP2882750A4 (en) | 2012-08-10 | 2016-08-17 | Epizyme Inc | INHIBITORS OF THE PROTEIN METHYLTRANSFERASE DOT1L AND METHOD OF USE THEREOF |
| EP2890704B1 (en) | 2012-08-31 | 2018-02-28 | Novartis AG | 2'-ethynyl nucleoside derivatives for treatment of viral infections |
| CA2883781A1 (en) | 2012-09-06 | 2014-03-13 | Epizyme, Inc. | Method of treating leukemia |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| EP2968387A4 (en) | 2013-03-15 | 2017-04-05 | Epizyme, Inc. | Methods of synthesizing substituted purine compounds |
| SI2986610T1 (en) | 2013-04-19 | 2018-04-30 | Incyte Holdings Corporation | Bicyclic heterocycles as inhibitors of FGFR |
| US9862743B2 (en) | 2013-10-11 | 2018-01-09 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| AU2015280248B2 (en) | 2014-06-24 | 2021-04-08 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| SG10201913036RA (en) | 2015-02-20 | 2020-02-27 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| CN104829620A (zh) * | 2015-04-08 | 2015-08-12 | 重庆华邦胜凯制药有限公司 | 一种制备氨基吡咯[2,3-d]嘧啶衍生物的方法 |
| CA2992278A1 (en) | 2015-08-06 | 2017-02-09 | Chimerix, Inc. | Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents |
| MA45925A (fr) | 2016-08-12 | 2019-06-19 | Janssen Biopharma Inc | Nucléosides et nucléotides substitués et leurs analogues |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| EP3684771A1 (en) | 2017-09-21 | 2020-07-29 | Chimerix, Inc. | MORPHIC FORMS OF 4-AMINO-7-(3,4-DIHYDROXY-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL)-2-METHYL-7H-PYRROLO[2,3-d]PYRIMIDINE-5-CARBOXAMIDE AND USES THEREOF |
| WO2019213544A2 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
| EP3788046A1 (en) | 2018-05-04 | 2021-03-10 | Incyte Corporation | Salts of an fgfr inhibitor |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| JP2022552324A (ja) | 2019-10-14 | 2022-12-15 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての二環式複素環 |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CN115151539A (zh) | 2019-12-04 | 2022-10-04 | 因赛特公司 | Fgfr抑制剂的衍生物 |
| US11897891B2 (en) | 2019-12-04 | 2024-02-13 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CN115916217A (zh) | 2020-04-14 | 2023-04-04 | 杨森制药公司 | 用于治疗戊型肝炎的炔基核苷类似物 |
| CA3215903A1 (en) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005511764A (ja) * | 2001-12-14 | 2005-04-28 | アルコン，インコーポレイテッド | 緑内障の処置のためのアミノアルキルベンゾフラン−５−オール化合物 |
| JP2005527499A (ja) * | 2002-02-13 | 2005-09-15 | メルク エンド カムパニー インコーポレーテッド | ヌクレオシド化合物を用いてオルトポックスウイルスの複製を阻害する方法 |
| JP2006505537A (ja) * | 2002-09-30 | 2006-02-16 | ジェネラブス テクノロジーズ，インコーポレイテッド | Ｃ型肝炎ウイルスの感染を治療するためのヌクレオシド誘導体 |
| US20040259934A1 (en) * | 2003-05-01 | 2004-12-23 | Olsen David B. | Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds |
| TW200838550A (en) * | 2007-02-09 | 2008-10-01 | Novartis Ag | Organic compounds |
-
2009
- 2009-08-04 WO PCT/EP2009/060125 patent/WO2010015643A1/en active Application Filing
- 2009-08-04 AR ARP090102985A patent/AR072906A1/es unknown
- 2009-08-06 US US12/536,615 patent/US20100144655A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20100144655A1 (en) | 2010-06-10 |
| WO2010015643A1 (en) | 2010-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
| AR077328A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
| AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
| AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
| AR078163A1 (es) | Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes | |
| AR082985A1 (es) | INHIBIDORES DE PI3K-d Y METODOS DE SU USO Y PREPARACION | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
| AR079327A1 (es) | Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida | |
| AR059957A1 (es) | DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER. | |
| UY32462A (es) | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 | |
| AR089774A1 (es) | Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| ES2530943T3 (es) | Derivados de la cromenona con actividad antitumoral | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| UY32611A (es) | Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750 | |
| AR054000A1 (es) | Compuesto de n-(fenilpropil)-sulfonamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento, producto de combinacion que comprende dicho compuesto y metodo para prepararlo | |
| UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
| AR080596A1 (es) | Compuestos alquilamido y composiciones farmaceuticas | |
| AR074021A1 (es) | Compuestos heterociclicos fusionados como moduladores del canal ionico | |
| AR080074A1 (es) | Naftiridinas sustituidas y su uso como medicamentos | |
| AR065249A1 (es) | Derivados nitrogenados condensados de analogos de nucleosidos, composiciones farmaceuticas que los contienen y usos para tratar y/o prevenir infecciones virales. | |
| CU20090048A7 (es) | Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| ECSP088257A (es) | Derivados de amida | |
| CU20100157A7 (es) | Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR061185A1 (es) | Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas. | |
| UY29892A1 (es) | Nuevos derivados de cromano, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |